At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
In Brief
A Phase 3 clinical trial evaluating rivaroxaban 2.5 mg, rivaroxaban 15 mg, and 6 other interventions for Atrial Fibrillation and Percutaneous Coronary Intervention. Completed, enrolled 2,124 participants across 348 sites in 25 countries.
Detailed Summary
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or prasugrel or ticagrelor).
Study Details
Timeline
Interventions
One 2.5 mg tablet twice daily for up to twelve months
One 15 mg tablet once daily for up to twelve months
One 10 mg tablet once daily for up to twelve months
Low-dose aspirin tablet once daily for twelve months
Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
One 75 mg tablet once daily for up to twelve months
One 10 mg tablet once daily for up to twelve months
One 90 mg tablet twice daily for up to twelve months